Allogene Therapeutics Inc (NAS:ALLO)
$ 2.07 -0.01 (-0.48%) Market Cap: 433.23 Mil Enterprise Value: 138.33 Mil PE Ratio: 0 PB Ratio: 0.77 GF Score: 28/100

Allogene Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 03:20PM GMT
Release Date Price: $24.65 (+1.86%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone. Thanks for joining us. We're really pleased to have the Allogene team with us. We have David Chang, President and CEO; and Eric Schmidt; CFO. I'm Salveen Richter, biotechnology analyst at Goldman Sachs.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

To start, David, you've had a broadening set of data from your allogeneic CAR T portfolio over the last year. How is your understanding of the approach been refined as you -- as yourselves and others have worked here to move candidates forward? And help us understand what's still left to be uncovered or understood about the implementation of allogeneic CAR Ts?

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

Yes, Salveen, first of all, thanks for hosting Allogene in your conference on your first day, and we are delighted to be here. And today with me is Eric Schmidt, our CFO, who

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot